Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).

Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).

Item

http://www.wikidata.org/entity/Q38612199

Q38612199

about

New developments in the pathology of malignant lymphoma. A review of the literature published from September-August 2017.

P2860

Q47162060-2D974B82-386E-4420-8684-3530AD1812A5

P2860

Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).

Item

http://www.wikidata.org/entity/Q38612199

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Immunohistochemical expression ...... mphoid tissue (MALT lymphoma).

@en

type

Item

label

Immunohistochemical expression ...... mphoid tissue (MALT lymphoma).

@en

prefLabel

Immunohistochemical expression ...... mphoid tissue (MALT lymphoma).

@en

P1476

Immunohistochemical expression ...... mphoid tissue (MALT lymphoma).

@en

P2093

Christoph Kornauth

http://www.w3.org/2001/XMLSchema#string

Ingrid Simonitsch-Klupp

http://www.w3.org/2001/XMLSchema#string

Julius Lukas

http://www.w3.org/2001/XMLSchema#string

Markus Raderer

http://www.w3.org/2001/XMLSchema#string

Werner Dolak

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Identification of a primary target of thalidomide teratogenicity

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.

P31

scholarly article

P356

10.1002/HON.2472

http://www.w3.org/2001/XMLSchema#string

P50

Marius E. Mayerhoefer

Barbara Kiesewetter

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28833354

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).

about

P2860

P2860

Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P921